European Journal of Dermatology
MENUImmediate hypersensitivity reaction to pegylated liposomal doxorubicin: management and outcome in four patients Volume 27, numéro 3, May-June 2017
Tableaux
2 EA 7379 EpiDermE (Epidémiologie en Dermatologie et Evaluation des Thérapeutiques),
UPEC,
Créteil,
France
UPEC,
Créteil,
France
11 French Study Group of Cutaneous Lymphoma (GFELC)
* Reprints
a Authors contributed equally
- Mots-clés : pegylated liposomal doxorubicin, allergy, pseudo-allergy, hypersensitivity, cutaneous lymphoma, Kaposi sarcoma
- DOI : 10.1684/ejd.2017.2986
- Page(s) : 271-4
- Année de parution : 2017
Hypersensitivity reactions (HSR) to pegylated liposomal doxorubicin (PLD; Caelyx®) have been reported, and symptoms usually resolve with drug withdrawal. However, the risk of relapse of severe HSR and prevention remain poorly described.